Dioguardi Mario, Cantore Stefania, Sovereto Diego, La Femina Lucia, Caloro Giorgia Apollonia, Spirito Francesca, Scacco Salvatore, Di Cosola Michele, Lo Muzio Lorenzo, Troiano Giuseppe, Ballini Andrea
Department of Clinical and Experimental Medicine, University of Foggia, Via Rovelli 50, 71122 Foggia, Italy.
Independent Researcher, Sorriso & Benessere-Ricerca e Clinica, 70129 Bari, Italy.
Life (Basel). 2022 Aug 19;12(8):1269. doi: 10.3390/life12081269.
The etiopathogenetic mechanisms involving tumor genesis, including alteration of cell proliferation, apoptosis, invasion, migration, and death, may lead to alterations in microRNAs (miR) expression. The hypothesis is that with the presence in the literature of recent studies conducted on miR-196a and miR-196b, it is possible to clearly determine, by aggregating the results, whether miR-196 upregulation in head and neck squamous cell carcinoma (HNSCC) tissues can represent a prognostic biomarker of survival through hazard ratio (HR) analysis. The systematic review was conducted following the indications of the PRISMA, and four electronic databases were used (Science Direct, SCOPUS, PubMed, and Cochrane Central), with the addition of gray literature. Combinations of keywords were used, such as miR-196, miR-196 AND HNSCC, microRNA AND HNSCC, LSCC AND miR-196, OSCC AND miR-196, OPSCC AND miR-196, HSCC AND miR-196. The meta-analysis and trial sequential analysis (TSA) were performed using RevMan 5.41 software and Stata 13 (StataCorp, College Station, TX, USA) with the implementation of the R 4.2 software. This search identified 1593 reports and, at the end of the selection, five articles were inserted. The results of the meta-analysis report an aggregate HR for overall survival (OS), between the highest and lowest miR-196 expression of 1.67, 95% CI: [1.16, 2.49]. In this meta-analysis, we found that the forest plot is in favor of higher OS in HNSCC patients, compared with the control, with low miR-196 expression, correlating this data with a favorable prognosis, which indicated the potential role of this miRNA in strengthening the therapy sensitiveness of the HNSCC patients. Consequently, the present systematic review places itself, together with other systematic reviews on this topic, in a key role to the finding of Phase 3 clinical trials studies, in search for a prognostic model of miR-196 for HNSCC. In conclusion, with the limitations of the meta-analysis, it can be argued that miRs of the miR-196 family could be independent prognostic biomarkers of survival for HNSCC.
涉及肿瘤发生的病因学发病机制，包括细胞增殖、凋亡、侵袭、迁移和死亡的改变，可能导致微小RNA（miR）表达的改变。假说是，鉴于文献中最近对miR-196a和miR-196b进行的研究，通过汇总结果，有可能通过风险比（HR）分析明确确定头颈部鳞状细胞癌（HNSCC）组织中miR-196上调是否可代表生存的预后生物标志物。按照PRISMA的指示进行系统评价，并使用了四个电子数据库（科学Direct、SCOPUS、PubMed和Cochrane Central），并补充了灰色文献。使用了关键词组合，如miR-196、miR-196 AND HNSCC、microRNA AND HNSCC、LSCC AND miR-196、OSCC AND miR-196、OPSCC AND miR-196、HSCC AND miR-196。使用RevMan 5.41软件和Stata 13（StataCorp，美国德克萨斯州大学站）并结合R 4.2软件进行荟萃分析和试验序贯分析（TSA）。该检索识别出1593篇报告，在筛选结束时，纳入了五篇文章。荟萃分析结果报告，miR-196表达最高与最低之间的总生存（OS）汇总HR为1.67，95%CI：[1.16，2.49]。在这项荟萃分析中，我们发现森林图显示，与对照组相比，miR-196低表达的HNSCC患者OS更高，将该数据与良好预后相关联，这表明该miRNA在增强HNSCC患者治疗敏感性方面的潜在作用。因此，本系统评价与关于该主题的其他系统评价一起，在寻找HNSCC的miR-196预后模型的3期临床试验研究中发挥关键作用。总之，鉴于荟萃分析的局限性，可以认为miR-196家族的miR可能是HNSCC生存的独立预后生物标志物。
